Aker Biomarine AS (AKBM) - Total Liabilities
Based on the latest financial reports, Aker Biomarine AS (AKBM) has total liabilities worth Nkr237.50 Million NOK (≈ $24.99 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AKBM operating cash flow to assess how effectively this company generates cash.
Aker Biomarine AS - Total Liabilities Trend (2016–2024)
This chart illustrates how Aker Biomarine AS's total liabilities have evolved over time, based on quarterly financial data. Check Aker Biomarine AS liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Aker Biomarine AS Competitors by Total Liabilities
The table below lists competitors of Aker Biomarine AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Cayi Vacuum Container Co. Ltd.
SHE:301004
|
China | CN¥936.89 Million |
|
Guangzhou Metro Design And Research
SHE:003013
|
China | CN¥3.17 Billion |
|
Matrix Design Co. Ltd. A
SHE:301365
|
China | CN¥319.46 Million |
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥1.50 Billion |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
China | CN¥35.63 Billion |
|
Vaudoise Assurances Holding SA
SW:VAHN
|
Switzerland | CHF6.46 Billion |
|
Plejd AB (publ)
F:3CA
|
Germany | €327.09 Million |
|
Dazzle Fashion Co Ltd
SHG:603587
|
China | CN¥628.44 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Aker Biomarine AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aker Biomarine AS market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.26 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aker Biomarine AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aker Biomarine AS (2016–2024)
The table below shows the annual total liabilities of Aker Biomarine AS from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr213.50 Million ≈ $22.47 Million |
-53.65% |
| 2023-12-31 | Nkr460.60 Million ≈ $48.47 Million |
+3.32% |
| 2022-12-31 | Nkr445.80 Million ≈ $46.91 Million |
+15.16% |
| 2021-12-31 | Nkr387.12 Million ≈ $40.74 Million |
+18.29% |
| 2020-12-31 | Nkr327.26 Million ≈ $34.44 Million |
-39.13% |
| 2019-12-31 | Nkr537.68 Million ≈ $56.58 Million |
+113.84% |
| 2018-12-31 | Nkr251.43 Million ≈ $26.46 Million |
-20.96% |
| 2017-12-31 | Nkr318.12 Million ≈ $33.47 Million |
+54.94% |
| 2016-12-31 | Nkr205.32 Million ≈ $21.61 Million |
-- |
About Aker Biomarine AS
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LY… Read more